The American Journal of Managed Care5 小时
Pain, Fatigue With Bimekizumab for PsA Tied to Swollen Joints
Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...
Le Lézard6 小时
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to ...
Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...
EurekAlert!20 小时
Relationship between SOCS1 levels and inhibition of GM-CSF signaling
A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...
PharmiWeb21 小时
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a ...
Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...